S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:ANIKAnika Therapeutics Stock Price, Forecast & News

$35.07
+0.52 (+1.51 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$34.68
Now: $35.07
$36.06
50-Day Range
$33.01
MA: $35.77
$38.57
52-Week Range
$22.01
Now: $35.07
$75.71
Volume151,122 shs
Average Volume174,132 shs
Market Capitalization$497.92 million
P/E Ratio56.56
Dividend YieldN/A
Beta1.12
Anika Therapeutics, Inc., together with its subsidiaries, provides orthopedic medicines for patients with degenerative orthopedic diseases and traumatic conditions in the United States and internationally. The company develops, manufactures, and commercializes therapeutic products based on its proprietary hyaluronic acid (HA) technology. Its orthobiologics products comprise ORTHOVISC, ORTHOVISC mini, MONOVISC, and CINGAL for the treatment of osteoarthritis of the knee; HYALOFAST, a biodegradable support for human bone marrow mesenchymal stem cells used for cartilage regeneration and as an adjunct for microfracture surgery; HYALONECT, a resorbable knitted fabric mesh; HYALOSS MATRIX, HYAFF fibers used to mix blood/bone grafts to form a paste for bone regeneration; and HYALOGLIDE, an ACP gel used in tenolysis treatment. The company's dermal products include wound care products that comprise HYALOMATRIX and HYALOFILL for the treatment of complex wounds, such as burns and ulcers, and for use in connection with the regeneration of skin; and ELEVESS, an aesthetic dermatology product. Its surgical products comprise HYALOBARRIER, a post-operative adhesion barrier for use in the abdomino-pelvic area; MEROGEL, a woven fleece nasal packing; and MEROGEL INJECTABLE, a viscous hydrogel. The company also offers ophthalmic products, including injectable HA products that are used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation; and veterinary products, which include HYVISC, an injectable HA product for the treatment of joint dysfunction in horses. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More
Anika Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ANIK
CUSIP03525510
Phone781-457-9000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$114.51 million
Cash Flow$2.55 per share
Book Value$20.21 per share

Profitability

Net Income$27.19 million

Miscellaneous

Employees133
Market Cap$497.92 million
Next Earnings Date10/22/2020 (Estimated)
OptionableOptionable
$35.07
+0.52 (+1.51 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for ANIK and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

How has Anika Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANIK stock has decreased by 3.6% and is now trading at $35.07.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Anika Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last year. There are currently 1 sell rating, 1 hold rating, 1 buy rating and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Anika Therapeutics
.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for Anika Therapeutics
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics Inc (NASDAQ:ANIK) posted its earnings results on Thursday, July, 30th. The biotechnology company reported ($0.54) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.21) by $0.33. The biotechnology company had revenue of $30.68 million for the quarter, compared to analyst estimates of $16.73 million. Anika Therapeutics had a return on equity of 8.05% and a net margin of 7.17%.
View Anika Therapeutics' earnings history
.

What price target have analysts set for ANIK?

4 Wall Street analysts have issued 12-month price targets for Anika Therapeutics' stock. Their forecasts range from $29.00 to $65.00. On average, they expect Anika Therapeutics' stock price to reach $53.75 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price.
View analysts' price targets for Anika Therapeutics
.

Has Anika Therapeutics been receiving favorable news coverage?

Media stories about ANIK stock have been trending neutral on Tuesday, InfoTrie Sentiment reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Anika Therapeutics earned a coverage optimism score of 0.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
View the latest news about Anika Therapeutics
.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a increase in short interest in January. As of January 31st, there was short interest totaling 2,740,000 shares, an increase of 15.6% from the January 15th total of 2,370,000 shares. Based on an average trading volume of 160,400 shares, the short-interest ratio is presently 17.1 days.
View Anika Therapeutics' Short Interest
.

Who are some of Anika Therapeutics' key competitors?

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Tesla (TSLA), CVS Health (CVS), Micron Technology (MU), Celgene (CELG), Walt Disney (DIS), Enterprise Products Partners (EPD) and NVIDIA (NVDA).

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Mr. Joseph G. Darling, CEO, Pres & Director (Age 61)
  • Ms. Sylvia Cheung, CFO, Treasurer & Sec. (Age 44)
  • Dr. Edward S. Ahn, Chief Technology & Strategy Officer (Age 47)
  • Mr. Thomas M. Finnerty, Chief HR Officer (Age 61)
  • Mr. Alexei Goraltchouk, VP of Operations

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Boston Trust Walden Corp (2.52%), Capital Management Corp VA (1.26%), Principal Financial Group Inc. (0.85%), Russell Investments Group Ltd. (0.76%), Foundry Partners LLC (0.53%) and Zweig DiMenna Associates LLC (0.43%). Company insiders that own Anika Therapeutics stock include Glenn R Larsen, James Loerop, Jeffery S Thompson, Joseph G Darling, Joseph L Bower, Raymond J Land and Sylvia Cheung.
View institutional ownership trends for Anika Therapeutics
.

Which major investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including 6 Meridian, UBS Group AG, Fisher Asset Management LLC, PNC Financial Services Group Inc., State Board of Administration of Florida Retirement System, and Texas Permanent School Fund. Company insiders that have sold Anika Therapeutics company stock in the last year include Glenn R Larsen, James Loerop, Joseph L Bower, Raymond J Land, and Sylvia Cheung.
View insider buying and selling activity for Anika Therapeutics
.

Which major investors are buying Anika Therapeutics stock?

ANIK stock was bought by a variety of institutional investors in the last quarter, including Capital Management Corp VA, Zweig DiMenna Associates LLC, Russell Investments Group Ltd., Boston Trust Walden Corp, Foundry Partners LLC, Brookstone Capital Management, Diversified Trust Co, and Rafferty Asset Management LLC.
View insider buying and selling activity for Anika Therapeutics
.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $35.07.

How big of a company is Anika Therapeutics?

Anika Therapeutics has a market capitalization of $497.92 million and generates $114.51 million in revenue each year. The biotechnology company earns $27.19 million in net income (profit) each year or $2.05 on an earnings per share basis. Anika Therapeutics employs 133 workers across the globe.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is www.anikatherapeutics.com.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at 781-457-9000 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.